Results 181 to 190 of about 7,886,175 (305)

Prognostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in ALD‐Related Myelopathy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background X‐linked adrenoleukodystrophy (X‐ALD) is a neurometabolic disorder caused by pathogenic variants in ABCD1, leading to slowly progressive spinal cord disease in nearly all affected men. Sensitive biomarkers to quantify disease severity and predict progression are needed for clinical care and trial design.
Eda G. Kabak, Marije M. C. Voermans, Hans Heijst, Charlotte E. Teunissen, Marc Engelen   +4 more
wiley   +1 more source

Safety and Efficacy of Mesenchymal Stem Cell Therapy in Aging Frailty: A Systematic Review. [PDF]

Int J Mol Sci
Poutouri E, Sotiropoulou M, Potoupnis M, Koliakos G, Kassi E, Tournis S, Anagnostis P.   +6 more
europepmc   +1 more source

Acute Kidney Injury After Mechanical Thrombectomy for Stroke in Patients With Pre‐Existing Renal Impairment

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Acute kidney injury (AKI) is a common but often underrecognized complication in ischemic stroke patients undergoing mechanical thrombectomy, particularly among those with pre‐existing renal impairment. This study evaluated the incidence, risk factors, and clinical impact of AKI in this high‐risk population.
Michał Borończyk, Marcel Pilarek, Emilia Jaworska, Natalia Kardas, Oliwia Barnaś, Julia Woźniak, Iga Machała, Julia Węgrzynek‐Gallina, Joanna Siuda, Anna Hawrot‐Kawecka, Anetta Lasek‐Bal   +10 more
wiley   +1 more source

Potential role of natural products in veterinary stem cell therapy. [PDF]

Stem Cell Res Ther
Shojaee A.
europepmc   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Stem cell therapy for erectile dysfunction: a systematic review and meta-analysis. [PDF]

Transl Androl Urol
Helvacı G, Bilgin A, Burnett AL, Sezen SF.   +3 more
europepmc   +1 more source

T1 Over Squared Proton Density Ratio to Characterize Multiple Sclerosis Lesions

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Differentiating remyelinated from demyelinated lesions in MS remains challenging without histological confirmation. This study introduces the T1‐to‐PD2 ratio (TPR) imaging approach and evaluates its ability to characterize MS lesions alongside other quantitative MRI (qMRI) metrics. Methods Thirty individuals with MS (mean age: 47.5 ± 
Sarah J. Wright, Scotty G. McKay, Jean Ramos Bou, Fen Bao, Vivian B. Truong, Chenyang Li, Li Jiang, Anza B. Memon, E. Mark Haacke, Yulin Ge, Yongsheng Chen   +10 more
wiley   +1 more source

Research progress on functionalized stem cell therapy strategies in wound healing. [PDF]

Front Cell Dev Biol
Ye T, Zhang W, Xu N, Ma W, Chai X.
europepmc   +1 more source

Baseline Neuroinflammation Stratifies TSPO‐PET Response to Disease‐Modifying Therapy in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate which baseline clinical and imaging characteristics best predict TSPO‐PET‐measurable reduction in glial activation following treatment of multiple sclerosis (MS), to utilize this information for designing more efficient biomarker‐based clinical trials targeting glial activation.
Marlene T. Morch, Markus Matilainen, Giulia N. Baldrighi, Marjo Nylund, Maija Saraste, Laura Airas   +5 more
wiley   +1 more source

Stem Cell Therapy for Parkinson's Disease: A Mechanistically Distinct Role for Muse Cells. [PDF]

J Clin Med
Mesches MH, Granholm AC, Paredes D, Mesches K, Oguma Y, Dezawa M.   +5 more
europepmc   +1 more source